Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Sees Large Increase in Short Interest

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) was the target of a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 46,799 shares, an increase of 34.3% from the November 30th total of 34,835 shares. Currently, 0.6% of the shares of the stock are sold short. Based on an average trading volume of 62,901 shares, the short-interest ratio is currently 0.7 days. Based on an average trading volume of 62,901 shares, the short-interest ratio is currently 0.7 days. Currently, 0.6% of the shares of the stock are sold short.

Burning Rock Biotech Stock Down 2.8%

NASDAQ:BNR opened at $20.58 on Tuesday. The company has a market cap of $221.44 million, a price-to-earnings ratio of -12.40 and a beta of 1.19. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.91 and a current ratio of 3.14. The stock’s fifty day moving average price is $16.26 and its two-hundred day moving average price is $10.19. Burning Rock Biotech has a 52-week low of $2.18 and a 52-week high of $24.18.

Hedge Funds Weigh In On Burning Rock Biotech

Hedge funds have recently added to or reduced their stakes in the company. Crcm LP raised its holdings in Burning Rock Biotech by 13.8% during the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after purchasing an additional 26,809 shares during the last quarter. Prospera Financial Services Inc bought a new position in shares of Burning Rock Biotech in the 3rd quarter valued at about $214,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Burning Rock Biotech during the third quarter worth approximately $26,000. Institutional investors own 30.03% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on BNR. Weiss Ratings reissued a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Wednesday, October 8th. Wall Street Zen raised Burning Rock Biotech from a “hold” rating to a “buy” rating in a report on Sunday, December 21st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.